Takis Biotech company information, funding & investors | Dealroom.co
Takis announces its strategy to generate a vaccine against the Omicron variant (B.1.1.529) of SARS-CoV-2 - Rottapharm Biotech
Home
Il vaccino anti Covid-19 di Takis-Rottapharm completa la fase 1 - Biotech - ANSA.it
Our Partners | IGEA Medical
ADVANCE Summer School on ATMPs (Cell and Gene Therapies) Development 2022 - EATRIS
Applied DNA Sciences and Takis Biotech
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models: Molecular Therapy
Vaccino Coronavirus, le tempistiche secondo Luigi Aurisicchio (AD Takis Biotech)
News
News
Takis - Symbola
Takis Biotech Interview - Italy Life Sciences 2021
COVID-eVax, il vaccino made in Italy efficace contro virus e varianti
Applied DNA and Takis Biotech partner on coronavirus vaccine
Home
Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNAT Vaccine Candidates Designed
COVID-eVax, il vaccino made in Italy efficace contro virus e varianti
Takis Biotech racing to develop coronavirus vaccine
Italian Biotech Company Takis Announce the Production of Antibodies Against SARS-CV-2 - Leaders League
ADVANCE 5-day Workshop on ATMPs Development - EATRIS
Takis Biotech Research moving forward!
Home
Applied DNA Sciences (NASDAQ: APDN) Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed - Applied DNA Sciences
